ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Otsuka acquires Visterra for $430 M
July 16, 2018Otsuka’s research areas are in psychiatric and neurological diseases, hematological cancers, and kidney, cardiovascular, and infectious diseases. -
Otsuka, X-Chem Partner for Drug Discovery
December 28, 2017Otsuka Pharmaceutical and X-Chem announced that they have signed a collaborative research agreement to advance the discovery process for new Otsuka drug compounds. -
Otsuka collaborates with X-Chem for new drug compounds
December 27, 2017X-Chem will utilize its DNA-encoded library (DEX) screening and informatics platform to search for novel drug leads for several Otsuka discovery targets. -
Otsuka Pharmaceutical to Acquire Neurovance
March 06, 2017Otsuka Pharmaceutical Co. announced an agreement with Neurovance, Inc. under which OPC has agreed to acquire Neurovance, a privately held, venture-funded, clinical stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADH
Pharma Sources Insight January 2025
